BRAF inhibitors and their immunological effects in malignant melanoma-Reference-Cited by-同舟云学术

BRAF inhibitors and their immunological effects in malignant melanoma

Published:2022-03-03 Issue:4 Volume:18 Page:347-362
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Adams Rebecca¹²,Coumbe Jack E M¹²,Coumbe Ben G T¹²,Thomas Jennifer²,Willsmore Zena¹,Dimitrievska Marija¹,Yasuzawa-Parker Monica¹,Hoyle Maximilian¹,Ingar Suhaylah¹,Geh Jenny L C¹³,MacKenzie Ross Alastair D³^ORCID,Healy Ciaran³,Papa Sophie⁴⁵,Lacy Katie E¹,Karagiannis Sophia N¹⁶^ORCID

Affiliation:

1. St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, London UK

2. Royal Marsden Hospital, London, UK

3. Department of Plastic Surgery at Guy’s, King's, and St. Thomas' Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK

4. Department of Medical Oncology, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK

5. ImmunoEngineering, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK

6. Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London UK

Funder

Guy’s and St Thomas’ Foundation Trust Charity, Melanoma Special Fund

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2022.2044796

Reference106 articles.

1. CRUK. Melanoma skin cancer statistics, cancer research UK February 2021. [cited 2022 Jan]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancerhttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancerhttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer.

2. Melanoma

3. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

4. The role of BRAF V600 mutation in melanoma

5. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Naphthoquinone Derivatives Targeting Melanoma;Current Topics in Medicinal Chemistry;2023-12

2. Reversing vemurafenib‐resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects;International Journal of Cancer;2023-06-09

3. Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis;BMC Cancer;2023-05-08

4. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?;Cancer and Metastasis Reviews;2023-04-06

5. High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma;Cells;2023-01-07